Source:http://linkedlifedata.com/resource/pubmed/id/18756910
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2008-9-1
|
pubmed:abstractText |
The aim of this study was to determine the association of bleeding as a complication of warfarin therapy with polymorphism of CYP2C9 gene (alleles 1, 2 and 3). The CYP2C9 is the main enzyme for warfarin metabolism. Study included 181 patients receiving warfarin for at least one month. Allele 1 of CYP2C9 gene (in 94.5%) and genotype *1/*1 (57.5%) prevailed. Allele 3 was found in 12.7% patients. Bleeding side-effects occurred in 18 patients (10%). Patients with allele *1 needed significantly higher maintenance warfarin dose (p=0.011). Those with allele *3 had significantly lower maintenance warfarin dose (p=0.005) and higher prothrombin time (PT) at induction (p=0.034). Bleeding occurred significantly more often in those with lower maintenance warfarin dose (p=0.017). Patients with allele *3 had increased risk of bleeding, with marginal significance (p=0.05). Polymorphism of CYP2C9 could determine dose of warfarin therapy and thus it could be related to the risk of bleeding complications. Allele *3 carriers need lower warfarin dose. Therefore, initially reduced warfarin induction dose in allele *3 carriers could avoid more prolonged PT and decrease the risk of bleeding complication.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0350-6134
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
32
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
557-64
|
pubmed:dateRevised |
2009-2-4
|
pubmed:meshHeading |
pubmed-meshheading:18756910-Adolescent,
pubmed-meshheading:18756910-Adult,
pubmed-meshheading:18756910-Aged,
pubmed-meshheading:18756910-Aged, 80 and over,
pubmed-meshheading:18756910-Anticoagulants,
pubmed-meshheading:18756910-Child,
pubmed-meshheading:18756910-Cytochrome P-450 Enzyme System,
pubmed-meshheading:18756910-Female,
pubmed-meshheading:18756910-Genotype,
pubmed-meshheading:18756910-Hemorrhage,
pubmed-meshheading:18756910-Humans,
pubmed-meshheading:18756910-Male,
pubmed-meshheading:18756910-Middle Aged,
pubmed-meshheading:18756910-Polymorphism, Genetic,
pubmed-meshheading:18756910-Prothrombin Time,
pubmed-meshheading:18756910-Warfarin
|
pubmed:year |
2008
|
pubmed:articleTitle |
Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy.
|
pubmed:affiliation |
Institute for Transfusion Medicine, University Hospital Osijek, Osijek, Croatia. samrdzija.marina@kbo.h
|
pubmed:publicationType |
Journal Article
|